Related Experiment Video
Updated: May 13, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification
Ningye Ma1, Jian Gao1, Xiaoao Pang1
1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.
Abstract:
Cancer is a major global public health challenge. Traditional treatments such as surgery, radiotherapy, and chemotherapy often show limited efficacy, minimal improvements in survival rates, and high recurrence risks. With limited therapeutic options for solid tumors, tumor immunotherapy, which harness the body's immune system, has gained significant attention. Oncolytic viruses (OVs) selectively infect and destroy tumor cells, induce immunogenic cell death (ICD) and stimulate antitumor immune responses. However, current OVs therapies, which are predominantly administered via intratumoral injection, have numerous limitations, including the need for guidance, suboptimal viral spread, extracellular matrix barriers, and immune clearance. These challenges hinder repeated dosing effectiveness and restrict its clinical applicability. Although genetic engineering has improved the tumor selectivity and immune activation of OVs, significant delivery challenges remain. Recently, optimizing pharmaceutical formulations to enhance tumor targeting and viral accumulation has emerged as a key approach to improving OV therapy and expanding clinical applicability. This review highlights the critical role of pharmaceutical formulations in biologics and outlines recent advances in OVs formulations. Specifically, we discuss strategies aimed at enhancing tumor targeting, reducing adverse effects, and promoting antitumor immunity. These strategies significantly enhance OV therapeutic potential and inform novel delivery systems for clinical translation.
Insights
Oncolytic viruses (OVs) show promise for cancer treatment by targeting tumors and stimulating immune responses. Pharmaceutical formulations are crucial for overcoming delivery challenges and improving the effectiveness of OV therapies for solid tumors.
Area of Science:
- Oncology
- Immunology
- Pharmaceutical Sciences
Background:
- Cancer remains a significant global health issue with limitations in traditional treatments.
- Tumor immunotherapy, particularly oncolytic viruses (OVs), offers a promising approach by selectively targeting and destroying cancer cells.
- Current OV therapies face delivery challenges, including intratumoral injection limitations, hindering widespread clinical application.
Purpose of the Study:
- To review the critical role of pharmaceutical formulations in enhancing oncolytic virus (OV) therapy.
- To outline recent advances in OV formulations for improved tumor targeting and delivery.
- To discuss strategies for reducing adverse effects and boosting antitumor immunity with OV formulations.
Main Methods:
- Review of current literature on oncolytic virus (OV) therapy and pharmaceutical formulations.
- Analysis of strategies for enhancing tumor targeting and viral accumulation.
- Evaluation of formulation approaches to improve OV delivery and efficacy.
Main Results:
- Pharmaceutical formulations are key to overcoming major delivery challenges in OV therapy.
- Optimized formulations can enhance tumor targeting, reduce adverse effects, and promote antitumor immunity.
- Advanced formulation strategies are crucial for the clinical translation of OV therapies.
Conclusions:
- Pharmaceutical formulations are essential for improving the therapeutic potential of oncolytic viruses (OVs).
- Novel delivery systems and formulation strategies are needed to enhance OV efficacy and clinical applicability.
- Further research into OV formulations will drive advancements in cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...